|
51. |
DINOPROSTONE VAGINAL INSERT FOR CERVICAL RIPENING AND LABOR INDUCTIONA META‐ANALYSIS |
|
Obstetrics & Gynecology,
Volume 97,
Issue 5,
2001,
Page 847-855
Edward Hughes,
Anthony Kelly,
Josephine Kavanagh,
Preview
|
PDF (609KB)
|
|
摘要:
ObjectiveTo compare dinoprostone 10 mg controlled-release vaginal insert with other forms of vaginal or cervical prostaglandin for cervical ripening.Data SourcesLiterature search strategy included review of the Cochrane database of randomized trials, on-line searching of MEDLINE, hand searching of bibliographies, and contact with authors of relevant reports.Methods of Study SelectionRandomized trials were included if they compared a dinoprostone slow-release vaginal insert with an alternative vaginal or cervical prostaglandin for cervical ripening and labor induction in women at term with singleton gestations. Primary end points were delivery by 24 hours postinsertion, uterine hypertonus with fetal heart change, and cesarean delivery rate. Study inclusion, validity assessment, and data extraction were carried out independently by two reviewers, and cross-checked for consistency. Data were combined when appropriate, using the Mantel–Haenszel fixed-effects method. Statistical heterogeneity was assessed using chi-square statistics.Tabulation, Integration, and ResultsNine relevant trials were identified, seven comparing the dinoprostone 10 mg vaginal insert with dinoprostone gel and two with misoprostol. Five trials reported adequate methods for randomization concealment. None were double blind. The likelihood of delivery by 24 hours was similar with the vaginal insert and alternatives: common odds ratio (OR) 0.80 (95% confidence interval [CI] 0.56, 1.15). Uterine hypertonus with change in fetal heart and cesarean delivery rate were also similar: common OR 1.19 (95% CI 0.56, 2.54) and 0.78 (95% CI 0.56, 1.08), respectively. The secondary end points of mean time to delivery and delivery by 12 hours appeared to favor misoprostol-dinoprostone gel. However, data for these end points were heterogeneous and their combination is therefore of limited value and potentially misleading.ConclusionNo clinically significant differences were identified between the vaginal insert and alternatives used for cervical ripening at term.
ISSN:0029-7844
出版商:OVID
年代:2001
数据来源: OVID
|
52. |
TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTSA REVIEW |
|
Obstetrics & Gynecology,
Volume 97,
Issue 5,
2001,
Page 855-866
Marian Mourits,
Elisabeth De Vries,
Pax Willemse,
Klaske Ten Hoor,
Harry Hollema,
Ate Van der Zee,
Preview
|
PDF (266KB)
|
|
摘要:
ObjectiveTo review the literature on tamoxifen side effects on the female genital tract and psychosexual function in premenopausal and postmenopausal women.Data SourcesWe used the English-language literature in MEDLINE and reference lists from selected articles. Search terms included: “tamoxifen and estrogen receptor,” “transcription activation,” “premenopause,” “postmenopause,” “vaginal epithelium,” “uterus,” “endometrial hyperplasia,” “polyps,” “endometrial cancer,” “sonography,” “sonohysterography,” “hysteroscopy,” “myometrium,” “myoma,” “sarcoma,” “endometriosis,” “ovarian cysts,” “hot flushes,” “concentration problems,” “sleep disturbance,” “vaginal dryness,” “sexual function,” “libido,” “dyspareunia,” and “quality of life.” No study-type restrictions were imposed.Methods of Study SelectionWith respect to clinical studies we included case cohort studies, observational studies; if no trials were available on a subject, case reports published in peer-reviewed journals were selected. For the discussion on endometrial surveillance of tamoxifen users, letters and editorials published in peer-reviewed journals also were used. Subjects of interest were mechanism of action of tamoxifen, tamoxifen and the vaginal epithelium, endometrium, mesenchymal tumors of the uterus, ovaries, sexual function, and vasomotor instability.Tabulation, Integration, and ResultsEligible studies were analyzed to determine their usefulness in this review. Data from trials that evaluated tamoxifen side effects on specific genital tissues were combined, with special interest in differentiation of side effects in premenopausal and postmenopausal women. Weighted estimates of severity and extent of side effects were usually not possible because of lack of randomized trials. Only the risk of endometrial cancer in relation to tamoxifen treatment could be estimated.ConclusionThe gynecologic side effects of tamoxifen are diverse and reflect the complexity of its mechanism of action, with agonistic and antagonistic effects on various tissues, depending on the ambient estradiol concentration and hence menopausal status of the patient. The most frequently reported side effect was hot flushes, and the most worrisome gynecologic side effect was a two- to three-fold increased risk of endometrial cancer in postmenopausal women. Despite its side effects, the benefits of tamoxifen in controlling breast cancer or prevention of its relapse are still without debate.
ISSN:0029-7844
出版商:OVID
年代:2001
数据来源: OVID
|
|